New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX) Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more eff
워싱턴, 2025년 10월 29일 -- 미국 영장류학회지(American Journal of Primatology)에 최근 게재된 한 논문은 긴꼬리원숭이(Macaca fascicularis)와 관련해 국제자연보전연맹(IUCN)이 내린 결정의 근거가 된 연구 결과를 비판했다. '널리 분포한 영장류의 개체수 추산(Estimating the Abundance of Widely Distributed Primates)'이라는 제목의 이 논문은 IUCN이 채택한 과학적 연구 결과는 "허점을 안고 있어서 영장류의 전 세계 개체수를 턱없이 적게 추정하는 문제를 초래한다"고 결론지었다. 또한 이 논문은 이러한 개체수가 "서식지 적합성과 개체 밀도 간의 전혀 현실적이지 않은 상관관계"를 근거로 추산되었다고 주장했다. 해당 기사는 https://onlinelibrary.wiley.com/doi/full/10.1002/ajp.70082에서 확인할 수 있다. 미국 영장류학회지는 미국영장류학회(American Society of Primatologists)에서 공식적으로 발간하는 학술지이다. 미국영장류학회의
CONSHOHOCKEN, Pa., Oct. 29, 2025 -- Suvoda (recently merged under common ownership with Greenphire), a global clinical trial technology company specializing in software solutions to address trial complexity in mission-critical, time-sensitive moments, today announced the release of its unified patient mobile app. The Suvoda app is a single, intuitive experience that will bring visit scheduling, questionnaires, travel information, receipt submission, and reimbursement tracking into one place to reduce the logistical burden for clinical trial participants. The new patient app com
BERLIN and BALTIMORE, Oct. 29, 2025 -- ICHORtec GmbH is pleased to announce an expanded research collaboration with the laboratory of Professor Gregory A. Newby in the Department of Genetic Medicine at the Johns Hopkins University School of Medicine. This partnership, aligned with the International Year of Quantum Science and Technology (IYQ) 2025, leverages ICHORtec's proprietary Quantum Fluorimetry of Molecular Binding (Q-FMB®) technology to advance the precision of CRISPR guide RNA (gRNA) design and evaluation, minimizing off-target effects in gene editing therapies. The collabo
Peer-reviewed (in-press) study finds serum-based antibody tests align, but milk results vary—calling for improved milk-specific diagnostics to strengthen herd surveillance and profitability CARLSBAD, Calif., Oct. 29, 2025 -- Pictor Holdings Inc. today announced new peer-reviewed data showing close agreement between commercial antibody tests when used on serum, but higher variability when used on milk—findings that highlight the need for milk-specific diagnostic standards to scale Johne's disease surveillance. Johne's disease costs the U.S. dairy industry an estimated $19
ISHRS Hosts Live Surgery Workshop in Bucharest, Romania, November 7-9, 2025, focusing on hair repair CHICAGO, Oct. 29, 2025 -- According to a recent member survey conducted by the International Society of Hair Restoration Surgery (ISHRS), the impact of black-market hair transplant clinics continues to reverberate around the world – with more clinics opening and more complications for the countless victims of these unscrupulous practices. Case in point: earlier this month, Dubai police arrested a man running an illegal hair transplant clinic from an apartment. &quo
[ 메디채널 김갑성 기자 ] 상하이 2025년 10월 29일 -- 스마티 덴티 테크놀로지(Smartee Denti-Technology)와 스트라우만 그룹(Straumann Group)이 전략적 제휴를 선언했다. 제휴의 주요 내용은 차세대 교정 플랫폼 공동 개발, 투명 교정기 기술 공동 혁신, 스트라우만의 스마티 지분 투자(한 자릿수 비율) 등이다. 준펑 야오(Junfeng Yao) 스마티 설립자 겸 CEO는 "스마티와 스트라우만 그룹 간의 이번 전략적 협력은 각자의 강점을 결합해 영업력을 극대화하는 전략인 동시에 치과 산업의 미래를 선점하려는 포석이다"라고 말했다. 플로리안 키르쉬(Florian Kirsch) 스트라우만 그룹 글로벌 IDT 책임자 겸 부사장은 "스마티와 같이 좋은 기업을 글로벌 파트너로 두게 되어 든든하다. 양사는 함께 치아 교정 분야에서 혁신을 앞당기고 전 세계 의사와 환자들이 질 좋고 예측 가능한 치료를 더 쉽게 받을 수 있는 플랫폼을 구축할 계획이다"라고 말했다. 스마티는 중국 투명 교정기 시장의 선두주자로서 20년이 넘는 전문성을 바탕으로 혁신
[ 메디채널 김갑성 기자 ] Potential new treatment option for multiple myeloma patients in Korea. Expanded patient access through competitive pricing. SHANGHAI and NANJING, China and PLEASANTON, Calif., Oct. 29, 2025 -- Nanjing IASO Biotechnology ("IASO Bio"), today announced that it has signed an agreement with Korea's GC Cell to introduce the CAR-T therapy "Fucaso" (Equecabtagene Autoleucel) to the South Korean market for the treatment of multiple myeloma. This partnership aims to provide a new therapeutic option for Korean patients with multiple myeloma, and GC Cell p
SHIJIAZHUANG, China, Oct. 29, 2025 -- A News Report from Great Wall New Media -- Among Hebei Province's 107 key specialized industrial clusters, the biopharmaceutical cluster in Shijiazhuang High-Tech Zone has emerged as a model of high-quality development and a key engine driving Hebei's integration into the global health industry chain. The cluster has established a comprehensive industrial system covering R&D, manufacturing, distribution, and supporting services. Centered in the Shijiazhuang High-Tech Zone, the cluster recorded an output value exceeding 125.72
[ 메디채널 김갑성 기자 ] The first-of-its-kind community awareness movement, supported by GSK, aims to provide seniors and caregivers with information about shingles, its health risks, and available preventive measures. SINGAPORE, Oct. 29, 2025 -- Five social service agencies — Diabetes Singapore, Lion Befrienders, Presbyterian Community Services, SASCO, and TOUCH Community Services —launched Singapore's first-of-its-kind shingles awareness movement at a 1960s/1970s nostalgia-themed event, "Shielding from Shingles". The initiative encourages older adults and their caregivers to lear